143 related articles for article (PubMed ID: 2062324)
21. Molecular identification of Cryptococcus neoformans serotypes.
Enache-Angoulvant A; Chandenier J; Symoens F; Lacube P; Bolognini J; Douchet C; Poirot JL; Hennequin C
J Clin Microbiol; 2007 Apr; 45(4):1261-5. PubMed ID: 17287323
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.
Casadevall A; Cleare W; Feldmesser M; Glatman-Freedman A; Goldman DL; Kozel TR; Lendvai N; Mukherjee J; Pirofski LA; Rivera J; Rosas AL; Scharff MD; Valadon P; Westin K; Zhong Z
Antimicrob Agents Chemother; 1998 Jun; 42(6):1437-46. PubMed ID: 9624491
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
24. Chemical characterization of capsular polysaccharide from Cryptococcus neoformans serotype A-D.
Ikeda R; Nishikawa A; Shinoda T; Fukazawa Y
Microbiol Immunol; 1985; 29(10):981-91. PubMed ID: 3908888
[TBL] [Abstract][Full Text] [Related]
25. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
Parker CJ; Baker PJ; Rosse WF
J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
[TBL] [Abstract][Full Text] [Related]
26. C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase.
Andersson J; Ekdahl KN; Larsson R; Nilsson UR; Nilsson B
J Immunol; 2002 Jun; 168(11):5786-91. PubMed ID: 12023380
[TBL] [Abstract][Full Text] [Related]
27. Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.
Blackstock R; Murphy JW
Infect Immun; 1997 Oct; 65(10):4114-21. PubMed ID: 9317016
[TBL] [Abstract][Full Text] [Related]
28. [Alternative complement pathway].
Jouvin MH; Kazatchkine M
Sem Hop; 1984 May; 60(19):1371-8. PubMed ID: 6326330
[TBL] [Abstract][Full Text] [Related]
29. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
30. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.
Gates-Hollingsworth MA; Kozel TR
Mol Microbiol; 2009 Oct; 74(1):126-138. PubMed ID: 19758241
[TBL] [Abstract][Full Text] [Related]
32. Comparison of serological and chemical characteristics of capsular polysaccharides of Cryptococcus neoformans var. neoformans serotype A and Cryptococcus albidus var. albidus.
Ikeda R; Matsuyama H; Nishikawa A; Shinoda T; Fukazawa Y
Microbiol Immunol; 1991; 35(2):125-38. PubMed ID: 1886490
[TBL] [Abstract][Full Text] [Related]
33. Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense.
Devine DV; Falk RJ; Balber AE
Infect Immun; 1986 Apr; 52(1):223-9. PubMed ID: 3633873
[TBL] [Abstract][Full Text] [Related]
34. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.
Kozel TR; Weinhold LC; Lupan DM
Infect Immun; 1996 Aug; 64(8):3360-8. PubMed ID: 8757876
[TBL] [Abstract][Full Text] [Related]
35. Antigenic structure of Cryptococcus neoformans capsular polysaccharides.
Kozel TR
Immunol Ser; 1989; 47():63-86. PubMed ID: 2484982
[No Abstract] [Full Text] [Related]
36. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase.
Strunk RC; Webster RO
Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899
[TBL] [Abstract][Full Text] [Related]
37. Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable.
De Jesus M; Chow SK; Cordero RJ; Frases S; Casadevall A
Eukaryot Cell; 2010 Jul; 9(7):1018-28. PubMed ID: 20061411
[TBL] [Abstract][Full Text] [Related]
38. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
Pangburn MK; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
[TBL] [Abstract][Full Text] [Related]
39. Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene.
Chang YC; Cherniak R; Kozel TR; Granger DL; Morris LC; Weinhold LC; Kwon-Chung KJ
Infect Immun; 1997 May; 65(5):1584-92. PubMed ID: 9125534
[TBL] [Abstract][Full Text] [Related]
40. Role of complement in protection against Cryptococcus gattii infection.
Mershon KL; Vasuthasawat A; Lawson GW; Morrison SL; Beenhouwer DO
Infect Immun; 2009 Mar; 77(3):1061-70. PubMed ID: 19114546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
